The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.

Abstract

BACKGROUND:

A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks.

OBJECTIVE:

To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations.

METHOD:

A retrospective study in 34 patients.

RESULTS:

Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease.

CONCLUSION:

Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established.

• Authors: Hessel H van der Zee, Jurr Boer, Errol P Prens, Gregor B E Jemec
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 219 Issue 2 Pg. 143-7 ( 2009) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 19590174 (Publication Type: Journal Article)
• Copyright: Copyright 2009 S. Karger AG, Basel.

Chemical References

• Clindamycin
• Rifampin

Topics

• Administration, Oral
• Adult
• Clindamycin (administration & dosage)
• Cohort Studies
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Hidradenitis Suppurativa (diagnosis, drug therapy)
• Humans
• Male
• Middle Aged
• Patient Satisfaction
• Quality of Life
• Retrospective Studies
• Rifampin (administration & dosage)
• Severity of Illness Index
• Treatment Outcome
• Young Adult